Literature DB >> 1867522

Lovastatin inhibits gallstone formation in the cholesterol-fed prairie dog.

K D Saunders1, J A Cates, M Z Abedin, S Rege, S F Festekdjian, W Howard, J J Roslyn.   

Abstract

The efficacy of lovastatin, an inhibitor of hepatic cholesterol synthesis in the prevention of cholesterol gallstone formation, was evaluated in the prairie dog model. Two groups of animals were maintained on either nonlithogenic or 1.2% cholesterol-enriched chow for 21 days. Seven of the animals in each group received lovastatin, and the remaining six received only distilled water. All of the cholesterol-fed/water-treated animals had crystals and 83% had gallstones, but none of the cholesterol-fed/lovastatin-treated animals had gallstones and only three had microscopic crystals. These data indicate that lovastatin inhibits cholesterol gallstone formation in a diet-induced model of gallstone disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1867522      PMCID: PMC1358514          DOI: 10.1097/00000658-199108000-00009

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  20 in total

1.  Early changes in bile composition and gallstone formation induced by a high cholesterol diet in prairie dogs.

Authors:  L DenBesten; S Safaie-Shirazi; W E Connor; S Bell
Journal:  Gastroenterology       Date:  1974-05       Impact factor: 22.682

2.  Effect of high and low doses of ursodeoxycholic acid on gallstone dissolution in humans.

Authors:  G Salen; A Colalillo; D Verga; E Bagan; G S Tint; S Shefer
Journal:  Gastroenterology       Date:  1980-06       Impact factor: 22.682

3.  Determination of serum calcium by means of orthocresolphthalein complexone.

Authors:  H V Connerty; A R Briggs
Journal:  Am J Clin Pathol       Date:  1966-03       Impact factor: 2.493

Review 4.  Animal models of human cholesterol gallstone disease: a review.

Authors:  N Gurll; L DenBesten
Journal:  Lab Anim Sci       Date:  1978-08

5.  Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels.

Authors:  B Angelin; S Ewerth; K Einarsson
Journal:  J Lipid Res       Date:  1983-04       Impact factor: 5.922

6.  Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation.

Authors:  G M Logan; W C Duane
Journal:  Gastroenterology       Date:  1990-06       Impact factor: 22.682

7.  Critical tables for calculating the cholesterol saturation of native bile.

Authors:  M C Carey
Journal:  J Lipid Res       Date:  1978-11       Impact factor: 5.922

8.  Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: a comparative randomized study.

Authors:  E Roda; F Bazzoli; A M Labate; G Mazzella; A Roda; C Sama; D Festi; R Aldini; F Taroni; L Barbara
Journal:  Hepatology       Date:  1982 Nov-Dec       Impact factor: 17.425

9.  The formation of abnormal bile and cholesterol gallstones from dietary cholesterol in the prairie dog.

Authors:  D E Brenneman; W E Connor; E L Forker; L DenBesten
Journal:  J Clin Invest       Date:  1972-06       Impact factor: 14.808

Review 10.  Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety.

Authors:  L J Schoenfield; J M Lachin
Journal:  Ann Intern Med       Date:  1981-09       Impact factor: 25.391

View more
  4 in total

1.  Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.

Authors:  F X Caroli-Bosc; P Le Gall; P Pugliese; B Delabre; C Caroli-Bosc; J F Demarquay; J P Delmont; P Rampal; J C Montet
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

Review 2.  Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.

Authors:  Helen H Wang; Piero Portincasa; Ornella de Bari; Kristina J Liu; Gabriella Garruti; Brent A Neuschwander-Tetri; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2013-02-19       Impact factor: 4.686

3.  Statin use and the risk of cholecystectomy in women.

Authors:  Chung-Jyi Tsai; Michael F Leitzmann; Walter C Willett; Edward L Giovannucci
Journal:  Gastroenterology       Date:  2009-01-24       Impact factor: 22.682

4.  Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs.

Authors:  Mohammad Z Abedin; Seth C Narins; Eun H Park; Peter R Smith; Kimberly S Kirkwood
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.